Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome

Seminars in Hematology

Volumn 45, Issue 1, 2008, Pages 49-59

  Barrett, A John ^a   Savani, Bipin N ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b Vanderbilt University Transplant Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; QUININE; THYMOCYTE ANTIBODY;

AGING; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEALTH HAZARD; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; MORTALITY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; T CELL DEPLETION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 37549051777     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.10.005     Document Type: Article

References (79)

1. Steensma D.P., and Bennett J.M. The myelodysplastic syndromes: Diagnosis and treatment. Mayo Clin Proc 81 (2006) 104-130
2. Ingram W., Lim Z.Y., and Mufti G.J. Allogeneic transplantation for myelodysplastic syndrome (MDS). Blood Rev 21 (2007) 61-71
3. Finke J., and Nagler A. Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning-Is there still an upper age limit?. A focus on myeloid neoplasia. Leukemia 21 (2007) 1357-1362
4. Schiffer C.A. Clinical issues in the management of patients with myelodysplasia. Hematology Am Soc Hematol Educ Program (2006) 205-210
5. McCarty J. Transplant strategies for myelodysplastic syndrome. Best Pract Res Clin Haematol 17 (2004) 559-572
6. Sierra J., Perez W.S., Rozman C., Carreras E., Klein J.P., Rizzo J.D., et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100 (2002) 1997-2004
7. Runde V., de Witte T., Arnold R., Gratwohl A., Hermans J., van Biezen A., et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21 (1998) 255-261
8. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
9. Graef T., Vaupel M., Fenk R., Ruf L., Zohren F., Germing U., et al. Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation. Hematol Oncol 25 (2007) 170-177
10. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 23 (2005) 7594-7603
11. Armand P., Kim H.T., Cutler C.S., Ho V.T., Koreth J., Alyea E.P., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109 (2007) 4586-4588
12. Scott B.L., Storer B.E., Greene J.E., Hackman R.C., Appelbaum F.R., and Deeg H.J. Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. Biol Blood Marrow Transplant 13 (2007) 345-354
13. Deeg H.J., Shulman H.M., Anderson J.E., Bryant E.M., Gooley T.A., Slattery J.T., et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95 (2000) 1188-1194
14. Deschler B., de Witte T., Mertelsmann R., and Lubbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: Problems and approaches. Haematologica 91 (2006) 1513-1522
15. Sorror M.L., Maris M.B., Storer B., Sandmaier B.M., Diaconescu R., Flowers C., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplantation comorbidities. Blood 104 (2004) 961-968
16. de Witte T., Hermans J., Vossen J., Bacigalupo A., Meloni G., Jacobsen N., et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110 (2000) 620-630
17. Cutler C.S., Lee S.J., Greenberg P., Deeg H.J., Perez W.S., Anasetti C., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104 (2004) 579-985
18. de Witte T., Zwaan F., Hermans J., Vernant J., Kolb H., Vossen J., et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 74 (1990) 151-155
19. Anderson J.E., Appelbaum F.R., Schoch G., Gooley T., Anasetti C., Bensinger W.I., et al. Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors. Blood 87 (1996) 51-58
20. Deeg H.J., Storer B., Slattery J.T., Anasetti C., Doney K.C., Hansen J.A., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100 (2002) 1201-1207
21. Appelbaum F.R., and Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score. Leukemia 12 suppl 1 (1998) S25-S29
22. Anderson J.E., Appelbaum F.R., Fisher L.D., Schoch G., Shulman H., Anasetti C., et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82 (1993) 677-681
23. Ho A.Y., Pagliuca A., Kenyon M., Parker J.E., Mijovic A., Devereux S., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 104 (2004) 1616-1623
24. Parker J.E., Shafi T., Pagliuca A., Mijovic A., Devereux S., Potter M., et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: Interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 119 (2002) 144-154
25. Martino R., Iacobelli S., Brand R., Jansen T., van Biezen A., Finke J., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108 (2006) 836-846
26. Nakai K., Kanda Y., Fukuhara S., Sakamaki H., Okamoto S., Kodera Y., et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 19 (2005) 396-401
27. de Witte T., Suciu S., Peetermans M., Fenaux P., Strijckmans P., Hayat M., et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 9 (1995) 1805-1811
28. Castro-Malaspina H., Harris R.E., Gajewski J., Ramsay N., Collins R., Dharan B., et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99 (2002) 1943-1951
29. Venditti A., Maurillo L., Buccisano F., Del Pricipio G., Mazzone C., Tamburini A., et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia 17 (2003) 2178-2182
30. Scott B.L., Storer B., Loken M.R., Storb R., Appelbaum F.R., and Deeg H.J. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 11 (2005) 65-73
31. Oran B., Giralt S., Saliba R., Hosing C., Popat U., Khouri I., et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 13 (2007) 454-462
32. Appelbaum F.R., Clift R.A., Buckner C.D., Stewart P., Storb R., Sullivan K.M., et al. Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. Blood 61 (1983) 949-953
33. Platzbecker U., Thiede C., Fussel M., Geissler G., Illmer T., Mohr B., et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 20 (2006) 707-714
34. Schmid C., Schleuning M., Ledderose G., Tischer J., and Kolb H.J. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23 (2005) 5675-5687
35. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
36. Barrett A.J., Rezvani K., Solomon S., Dickinson A.M., Wang X.N., Stark G., et al. New developments in allotransplant immunology. Hematology Am Soc Hematol Educ Program (2003) 350-371
37. Sutton L., Chastang C., Ribaud P., Jouet J.P., Kuentz M., Attal M., et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: A long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 88 (1996) 358-365
38. Barrett A.J., and Savani B.N. Stem cell transplantation with reduced-intensity conditioning regimens: A review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 20 (2006) 1661-1672
39. Shimoni A., Hardan I., Shem-Tov N., Yeshurun M., Yerushalmi R., Avigdor A., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 20 (2006) 322-328
40. Alyea E.P., Kim H.T., Ho V., Cutler C., Gribben J., DeAngelo D.J., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105 (2005) 1810-1814
41. de Lima M., Anagnostopoulos A., Munsell M., Shahjahan M., Ueno N., Ippoliti C., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 865-872
42. Solomon S.R., Savani B.N., Childs R., Montero A., Boss C., Read E.J., et al. Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome. Biol Blood Marrow Transplant 11 (2005) 619-626
43. Van Biesen K., Artz A., Smith S., Cao D., Rich S., Godley L., et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23 (2005) 5728-5738
44. Scott B.L., Sandmaier B.M., Storer B., Maris M.B., Sorror M.L., Maloney D.G., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis. Leukemia 20 (2006) 128-135
45. de Lima M., and Giralt S. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol 43 (2006) 107-117
46. Estey E., de Lima M., Tibes R., Pierce S., Kantarjian H., Champlin R., et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 109 (2007) 1395-1400
47. Gupta V., Daly A., Lipton J.H., Hasegawa W., Chun K., Kamel-Reid S., et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 11 (2005) 764-772
48. Wallen H., Gooley T.A., Deeg H.J., Pagel J.M., Press O.W., Appelbaum F.R., et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 23 (2005) 3439-3446
49. Guardiola P., Runde V., Bacigalupo A., Ruutu T., Locatelli F., Boogaerts M.A., et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 99 (2002) 4370-4378
50. Ducastelle S., Ades L., Gardin C., Dombret H., Prebet T., Deconinck E., et al. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Haematologica 91 (2006) 373-376
51. de Witte T., Brand R., van B.A., Delforge M., Biersack H., Or R., et al. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. Haematologica 91 (2006) 750-756
52. Al-Ali H.K., Brand R., van Biezen A., Finke J., Boogaerts M., Fauser A.A., et al. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: A report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 21 (2007) 1745-1751
53. Oosterveld M., Suciu S., Verhoef G., Labar B., Belhabri A., Aul C., et al. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: Results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia 17 (2003) 859-868
54. de Witte T., Oosterveld M., and Muus P. Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome. Blood Rev 21 (2007) 49-59
55. Oosterveld M., Muus P., Suciu S., Koller C., Verhoef G., Labar B., et al. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia 16 (2002) 1615-1621
56. Gluckman E., Devergie A., Bourdeau-Esperou H., Thierry D., Traineau R., Auerbach A., et al. Transplantation of umbilical cord blood in Fanconi's anemia. Nouv Rev Fr Hematol 32 (1990) 423-425
57. Hwang W.Y., Samuel M., Tan D., Koh L.P., Lim W., and Linn Y.C. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol Blood Marrow Transplant 13 (2007) 444-453
58. Laughlin M.J. Unrelated cord blood allogeneic stem cell transplantation for MDS. Leuk Lymphoma 47 (2006) 569-570
59. Brunstein C.G., Baker K.S., and Wagner J.E. Umbilical cord blood transplantation for myeloid malignancies. Curr Opin Hematol 14 (2007) 162-169
60. Ooi J. The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome. Leuk Lymphoma 47 (2006) 599-602
61. Anderson J.E., Anasetti C., Appelbaum F.R., Schoch G., Gooley T.A., Hansen J.A., et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 93 (1996) 59-67
62. Arnold R., de Witte T., van Biezen A., Hermans J., Jacobsen N., Runde V., et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: An EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 21 (1998) 1213-1216
63. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: Efficacy and side effects. Bone Marrow Transplant 35 (2005) 225-231
64. Tauro S., Craddock C., Peggs K., Begum G., Mahendra P., Cook G., et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 23 (2005) 9387-9393
65. Perez-Simon J.A., Kottaridis P.D., Martino R., Craddock C., Caballero D., Chopra R., et al. Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100 (2002) 3121-3127
66. Remberger M., Storer B., Ringden O., and Anasetti C. Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 29 (2002) 391-397
67. Bondanza A., Valtolina V., Magnani Z., Ponzoni M., Fleischhauer K., Bonyhadi M., et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 107 (2006) 1828-1836
68. Solomon S.R., Mielke S., Savani B.N., Montero A., Wisch L., Childs R., et al. Selective depletion of alloreactive donor lymphocytes: A novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 106 (2005) 1123-1129
69. Shiobara S., Nakao S., Ueda M., Yamazaki H., Takahashi S., Asano S., et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: Indications and dose escalation. Ther Apher 5 (2001) 40-45
70. Oran B., Giralt S., Couriel D., Hosing C., Shpall E.J., de M.E., et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 21 (2007) 2540-2544
71. Kolb H.J., Schmid C., Tischer J., Haussmann A., Rank A., Schleuning M., et al. Allogeneic stem cell transplantation for MDS and sAML following reduced intensity conditioning and preemptive donor lymphocyte infusions. Blood 108 (2006) 324 (abstr)
72. Soriano A.S., Champlin R., McCormick G., Giralt S., Thall P.F., Komanduri K., et al. Maintenance therapy with 5-azacytidine (5-AC) after allogeneic stem cell transplantation (allo-SCT) for acute myelogenous leukemi (AML) and high risk myelodysplastic syndrome (MDS): A dose and schedule finding study. Blood 108 (2006) 3668 (abstr)
73. Melchert M., Kale V., and List A. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol 14 (2007) 123-129
74. Barrett A.J., and Rezvani K. Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias. Clin Exp Immunol 148 (2007) 189-198
75. Kolb H.J., Schmid C., Barrett A.J., and Schendel D.J. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103 (2004) 767-776
76. van der Straaten H.M., van Biesen A., Brand R., Schattenberg A.V., Egeler R.M., Barge R.M., et al. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. Haematologica 90 (2005) 1339-1345
77. Armand P., Kim H.T., DeAngelo D.J., Ho V.T., Cutler C.S., Stone R.M., et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 13 (2007) 655-664
78. Wong R., Shahjahan M., Wang X., Thall P.F., de Lima M., Khouri I., et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 11 (2005) 108-114
79. Nevill T.J., Shepherd J.D., Reece D.E., Barnett M.J., Nantel S.H., Klingemann H.G., et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 10 (1992) 445-450